Inactive Instrument

Social Capital Suvretta Holdings Corp. II Stock

Equities

DNAB

KYG8253U1031

Investment Holding Companies

Dynamic Chart
Social Capital Suvretta Holdings Corp. II(NasdaqCM:DNAB) dropped from NASDAQ Composite Index CI
Social Capital Suvretta Holdings Corp. II Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Social Capital Suvretta Holdings Corp. II Announces Resignation of Sean P. Nolan as Director CI
Social Capital Suvretta Holdings Corp. II Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Social Capital Suvretta Holdings Corp. II Auditor Raises 'Going Concern' Doubt CI
Social Capital Suvretta Holdings Corp. II Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Social Capital Suvretta Holdings Corp. II Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Social Capital Suvretta Holdings Corp. II Appoints Robert Berman to Its Board of Directors CI
Social Capital Suvretta Holdings Corp. II Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Social Capital Suvretta Holdings Corp. II Reports Earnings Results for the Ten Months Ended December 31, 2021 CI
Social Capital Suvretta Holdings Corp. II Auditor Raises 'Going Concern' Doubt CI
Certain Class B Ordinary Shares of Social Capital Suvretta Holdings Corp. II are subject to a Lock-Up Agreement Ending on 27-DEC-2021. CI
Social Capital Suvretta Holdings Corp. II Announces Board Changes CI
Social Capital Suvretta II : Prices Upsized $220 Million Initial Public Offering MT
Social Capital Suvretta Holdings Corp. II has completed an IPO in the amount of $220 million. CI
More news
Managers TitleAgeSince
Founder 38 21-02-24
Chief Executive Officer 47 21-02-24
Director of Finance/CFO 48 21-02-24
Members of the board TitleAgeSince
Chief Executive Officer 47 21-02-24
Founder 38 21-02-24
Director/Board Member 62 22-06-28
More insiders
Social Capital Suvretta Holdings Corp. II is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It has not selected any specific business combination target and has not engaged in any substantive discussions, directly or indirectly, with any business combination target. The Company intend to focus its search for a target business operating in the biotechnology industry and within the oncology subsector of such industry. The Company neither engages in any business operations nor generates any revenues.
More about the company